FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0	287				
Estimated average burden						
nours per response	e	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

pe Response	es)															
1. Name and Address of Reporting Person * SANDAGE BOBBY W PHD				2. Issuer Name and Ticker or Trading Symbol CORONADO BIOSCIENCES INC [CNDO]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
(Last) (First) (Middle) C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK				3. Date of Earliest Transaction (Month/Day/Year) 01/11/2012							X Director10% Owner X Officer (give title below) Other (specify below) President and CEO					
(Street) BURLINGTON, MA 01803				4. If Amendment, Date Original Filed(Month/Day/Year)							_X_ Form fil	6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
)	(State)	(Zip)		7	abl	le I - Non	-Der	ivative S	ecurit	ies Acq	uired, Disp	osed of, or l	Beneficially	Owned		
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea		Date	Execu	ecution Date, if	if (Code (Instr. 8)				Beneficially Owned Following Reported Transaction(s)			Ownership of Form:	7. Nature of Indirect Beneficial		
			(Mont	Month/Day/Year)		Code	V	Amount	(A) or (D)	Price		nstr. 3 and 4)		or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	
Stock, par	value	01/12/2012				P		1,000	A	\$ 5.195 <u>(1)</u>	2 1,500			D		
Stock, par	value	01/11/2012				P		500	A	\$ 5.28 (2)	500			D		
Report on a	separate line	for each class of sec	curities	beneficiall	y o	wned dire	ctly	or								
							con	tained i	n this	form a	re not req	uired to re	spond un	ess	EC 1474 (9- 02)	
												i				
	Date	Execution I any	Date, if	Code	on of I	of Derivative Securities Acquired A) or Disposed of (D) Instr. 3, 4, and 5)	er 6. Date Exercisable and Expiration Date (Month/Day/Year) (Month/Day/Year) Se (In 4)		nount of aderlying curities astr. 3 and	Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported	Owners: Form of Derivati Security Direct (I or Indirect (s) (I)	Ownership (Instr. 4) Oct			
	dd Address of GE BOBBY CONADO I GLAND E GTON, M. Stock, par Stock, par Report on a 2. Conversion or Exercise Price of Derivative	GE BOBBY W PHD (First) CONADO BIOSCIEN (GLAND EXECUTIV (Street) GTON, MA 01803 (State) Gecurity Stock, par value Stock, par value 2. 2. Conversion or Exercise Price of Derivative	d Address of Reporting Person *GE BOBBY W PHD (First) (Middle) (CONADO BIOSCIENCES, INC., 15 GLAND EXECUTIVE PARK (Street) GTON, MA 01803 (State) (Zip) 2. Transaction Date (Month/Day/Year) Stock, par value 01/12/2012 Stock, par value 01/11/2012 Report on a separate line for each class of second Execution Execution Execution Execution Execution Execution Energy (Month/Day/Year) 2. Table II - 2. (Month/Day/Year) 3. Transaction Execution Executi	d Address of Reporting Person 2. I GE BOBBY W PHD (COIF) (CONADO BIOSCIENCES, INC., 15 (STreet) GLAND EXECUTIVE PARK (Street) 2. Transaction Date (Month/Day/Year) Stock, par value 10/11/2012 Stock, par value 2. Transaction Date (Month/Day/Year) Table II - Deriva (e.g., p) 2. Transaction Date (Month/Day/Year) 3. Transaction Date (ag., p) 2. Transaction Date (month/Day/Year) 3. Transaction Date (month/Day/Year) 3. Transaction Date (month/Day/Year) 3. Transaction Date (month/Day/Year) 3. Transaction Date (month/Day/Year)	d Address of Reporting Person - GE BOBBY W PHD ONADO BIOSCIENCES, INC., 15 GLAND EXECUTIVE PARK (Street) 2. Issuer Nam CORONADO 3. Date of Earli 01/11/2012 4. If Amendme GTON, MA 01803 (State) 2. Transaction Date (Month/Day/Year) Stock, par value 01/12/2012 Stock, par value 01/11/2012 Table II - Derivative Secur (e.g., puts, calls, value) 2. Transaction Date (Month/Day/Year) Address of Reporting Person - CORONADO 01/11/2012 2. If Amendme 02/11/2012 2. Transaction Date (Month/Day/Year) Table II - Derivative Secur (e.g., puts, calls, value) 1. If Amendme 01/11/2012 2. Transaction Date (Month/Day/Year) 3. Date of Earli 01/11/2012 2. Transaction Date (Month/Day/Year) 3. Date of Earli 01/11/2012 4. If Amendme Execution Date, if Transaction Code (Instr. 8)	d Address of Reporting Person - GE BOBBY W PHD (Siret) (Middle) (O1/11/2012 GLAND EXECUTIVE PARK (Street) 4. If Amendment, I GTON, MA 01803 (State) (Zip) Table (Month/Day/Year) Stock, par value 01/12/2012 Stock, par value 01/11/2012 Stock, par value 01/11/2012 Table II - Derivative Securities beneficially of Exercise (Month/Day/Year) (Month/Day/Year) Table II - Derivative Securities (e.g., puts, calls, ward Conversion of Exercise (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) Table II - Derivative Securities (e.g., puts, calls, ward Conversion of Exercise (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Instr. 8)	d Address of Reporting Person * GE BOBBY W PHD (Middle) (CORONADO BIOSCIE (MONTH/DOUTE) (MONTH/DOUTE) (MONTH/DOUTE) (MONTH/DOUTE) (CORONADO BIOSCIE (CORONADO BIOSCIE (MONTH/DOUTE) (MONTH/DOUTE) (MONTH/DOUTE) (MONTH/DOUTE) (MONTH/DOUTE) (MONTH/DOUTE) (CORONADO BIOSCIE (MONTH/DOUTE) (MONT	d Address of Reporting Person 2 GE BOBBY W PHD (First) (ONADO BIOSCIENCES, INC., 15 GLAND EXECUTIVE PARK (Street) (Street) (Street) (Street) (Street) (Street) (Aliddle) (O1/11/2012 4. If Amendment, Date Original Incomplete Execution Date of Code (Instr. 8) (Month/Day/Year) (Month/Day/Year) (Stock, par value) (O1/12/2012 (Align Processes of Execution Date, if (Month/Day/Year) (Code (Instr. 8) (Code V) (Code	2. Issuer Name and Ticker or Trading Sy CORONADO BIOSCIENCES INC ORONADO BIOSC	2. Issuer Name and Ticker or Trading Symbol CORONADO BIOSCIENCES INC [CNE of DIADO BIOSCIENCES INC] (Month/Day/Year) (Street) (St	2. Issuer Name and Ticker or Trading Symbol CORONADO BIOSCIENCES INC [CNDO]	Ad Address of Reporting Person 2 EB BOBBY W PHD CORONADO BIOSCIENCES INC [CNDO] (Maddle) (ONADO BIOSCIENCES, INC, 15 GLAND EXECUTIVE PARK (Street) A. If Amendment, Date Original Filed(Month/Day/Year) (Stute) Code (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) Stock, par value O1/11/2012 P	2. Issuer Name and Ticker or Trading Symbol CORONADO BIOSCIENCES INC [CNDO] S. Relationship of Ref (Che Name and Ticker or Trading Symbol CORONADO BIOSCIENCES INC [CNDO] S. Relationship of Ref (Che Name and Ticker or Trading Symbol CORONADO BIOSCIENCES INC [CNDO] S. Relationship of Ref (Che Name and Ticker or Trading Symbol CORONADO BIOSCIENCES INC [CNDO] S. Detection (Che Name and Ticker or Trading Symbol CORONADO BIOSCIENCES INC [CNDO] S. Detection (Che Name and Ticker or Trading Symbol CORONADO BIOSCIENCES INC [CNDO] S. Detection (Che Name and Ticker or Trading Symbol CORONADO BIOSCIENCES INC [CNDO] S. Detection (Che Name and Ticker or Trading Symbol Coronado (Che Name and Ticker or Trading Symbol (Che Name and Ticker or Trading Symbol Coronado (Che Name and Ticker or Trading Symbol (Che Name and Ticker or	Security 2. Issuer Name and Ticker or Trading Symbol CORONADO BIOSCIENCES INC (Check all applic CORONADO BIOSCIENCES, INC., 15 Ol/11/2012 South President and Coronado Bioscience Ol/11/2012 South Prince Ol/11/2012 South Pr	Address of Reporting Person 2 E BOBRY W PHD O(10) (10) (10) (10) (10) (10) (10) (10)	

Reporting Owners

Barratina Orana Nama (Addana	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
SANDAGE BOBBY W PHD C/O CORONADO BIOSCIENCES, INC. 15 NEW ENGLAND EXECUTIVE PARK BURLINGTON, MA 01803	X		President and CEO				

Signatures

By: /s/ Dale Ritter as attorney-in-fact for Bobby W. Sandage, Jr.	01/12/2012
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

 Represents the weighted average purchase price for the reported transactions. The range of prices for such transactions was \$5.18 to \$5.20. The reporting person

- (1) undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- Represents the weighted average purchase price for the reported transactions. The range of prices for such transactions was \$5.28 to \$5.29. The reporting person (2) undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Dale Ritter and Robyn Hunter the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Coronado Biosciences, Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder, and any other forms or reports the undersigned may be required to file in connection with the undersigned's ownership, acquisition, or disposition of securities of the Company;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, or other form or report, and timely file such form or report with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to the Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 19 th day of December 2011.

/s/ Bobby W. Sandage, Jr. Signature